<qa>  What is the major endpoint of intraperitoneal tumor progression and survival?Patients with low-grade gastrointestinal adenocarcinoma and peritoneal carcinomatosis will undergo laparotomy and tumor debulking. Patients will be randomized at completion of tumor debulking to receive continuous hyperthermic peritoneal perfusion HIPEC,formerly CHPP with 250 mgm2 cisplatin and an intraperitoneal dwell of 5-fluorouracil 800 mgm2 and paclitaxel 125 mgm2 once between postoperative day 7 and 12. All patients will receive systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks starting 4 to 6 weeks after operation and continuing for four cycles. The major endpoint is time to intraperitoneal tumor progression and survival in patients stratified based on history of previous treatment with systemic chemotherapy yes vs. no, history of prior debulking surgery; and ability to optimally vs. suboptimally debulk intraperitoneal tumor burden. 